Strategies for Maximizing Growth in Puberty in Children with Short Stature

Pediatric Clinics of North America

Volumn 58, Issue 5, 2011, Pages 1167-1179

  Mauras, Nelly ^a,b  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Anastrozole; Aromatase; Aromatase inhibitors; GnRH analogues; Letrozole; Short stature

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BICALUTAMIDE; ESTROGEN; EXEMESTANE; GONADORELIN DERIVATIVE; GROWTH HORMONE; LETROZOLE; OXANDROLONE; PLACEBO; SPIRONOLACTONE; TAMOXIFEN; TESTOSTERONE;

ALBRIGHT SYNDROME; CHILD GROWTH; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ESTROGEN SYNTHESIS; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HUMAN; IDIOPATHIC SHORT STATURE; NONHUMAN; OLIGOSPERMIA; PRECOCIOUS PUBERTY; PUBERTY; REVIEW; SHORT STATURE; SIDE EFFECT; TESTOTOXICOSIS; VERTEBRA MALFORMATION;

EID: 80053602371     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2011.07.007     Document Type: Review

References (50)

1. Mauras N., Blizzard R.M., Link K., et al. Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon. J Clin Endocrinol Metab 1987, 64:596-601.
2. Martha P.M.J., Rogol A.D., Veldhuis J.D. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab 1989, 69:563-570.
3. Rose S.R., Municchi G., Barnes K.M., et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab 1991, 73:428-435.
4. Mauras N., Rogol A.D., Veldhuis J.D. Specific time-dependent actions of low-dose ethinyl estradiol administration on the episodic release of GH, FSH and LH in prepubertal girls with Turner's syndrome. J Clin Endocrinol Metab 1989, 69:1053-1058.
5. Mauras N., Rogol A.D., Veldhuis J.D. Increased hGH production rate after low-dose estrogen therapy in prepubertal girls with Turner's syndrome. Pediatr Res 1990, 28:626-630.
6. Mauras N., Attie K.M., Reiter E.O., et al. High-dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 2000, 85:3653-3660.
7. Paul D., Conte F.A., Grumbach M.M., et al. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995, 80:546-551.
8. Kletter G.B., Kelch R.P. Clinical review 60: effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab 1994, 79:331-334.
9. Pasquino A.M., Municchi G., Pucarelli I., et al. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty. J Clin Endocrinol Metab 1996, 81:948-951.
10. Balducci R., Toscano V., Mangiantini A., et al. Adult height in short normal adolescent girls treated with GnRHa and GH. J Clin Endocrinol Metab 1995, 80:3596-3600.
11. Cassorla F., Mericq V., Eggers M., et al. Effects of luteinizing hormone-releasing hormone analog-induced pubertal delay in growth hormone (GH)-deficient children treated with GH: preliminary results. J Clin Endocrinol Metab 1997, 82:3989-3992.
12. Adan L., Souberbielle J.C., Zucker J.M., et al. Adult height in 24 patients treated for GH deficiency and early puberty. J Clin Endocrinol Metab 1997, 82:229-233.
13. Lanes R., Gunczler P. Final height after combined growth hormone and gonadotropin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin Endocrinol (Oxf) 1998, 49:197-202.
14. Cara J.F., Kreiter M.L., Rosenfield R.L. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin-releasing hormone agonist and growth hormone. J Pediatr 1992, 120:709-715.
15. Carel J.C., Eugster E.A., Rogol A., et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009, 123:e752-e762.
16. Mauras N., Hayes V., Welch S., et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998, 83:1886-1892.
17. Mauras N., Hayes V., Yergey A.L. Profound hypogonadism has significant negative effects on calcium balance in males: a calcium kinetic study. J Bone Miner Res 1999, 14:577-582.
18. Yanovski J.A., Rose S.R., Municchi G., et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003, 348:908-917.
19. Smith E.P., Boyd J., Frank G.R. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med 1994, 331:1056-1061.
20. Carani C., Qin K., Simoni M. Effect of testosterone and estradiol in man with aromatase deficiency. N Engl J Med 1997, 1337:91-95.
21. Morishima A., Grumbach M.M., Simpson E.R., et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995, 80:3689-3698.
22. Gunther D.F., Calikoglu A.S., Underwood L.E. The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatr Res 2000, 46:269-273.
23. Chagin A.S., Lindberg M.K., Andersson N., et al. Estrogen receptor-beta inhibits skeletal growth and has the capacity to mediate growth plate fusion in female mice. J Bone Miner Res 2004, 19:72-77.
24. Mauras N., Lima J., Patel D., et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 2003, 88:5951-5956.
25. Mauras N, Bishop K, Merinbaum D, et al. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent onset gynecomastia. J Clin Endocrinol Metab, in press.
26. Mauras N., O'Brien K.O., Oerter Klein K., et al. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000, 85:2370-2377.
27. Wickman S., Sipila I., Ankarberg-Lindgren C., et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomized controlled trial. Lancet 2001, 357:1743-1748.
28. Hero M., Wickman S., Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol 2006, 64:510-513.
29. Hero M., Norjavaara E., Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005, 90:6396-6402.
30. Mauras N., Gonzalez de Pijem L., Hsiang H.Y., et al. Anastrozole increases predicted adult height of growth hormone deficient adolescent males treated with growth hormone: a randomized, double-blind, placebo-controlled multicenter trial for up to three years. J Clin Endocrinol Metab 2008, 93:823-831.
31. Salehpour S., Alipour P., Razzaghy-Azar M., et al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr 2010, 74:428-435.
32. Eugster E.A., Rubin S.D., Reiter E.O., et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003, 143:60-66.
33. Feuillan P., Calsi K., Hill S., et al. Letrozole treatment of precocious puberty in girls with the McCune-albright syndrome: a pilot study. J Clinical Endocrinol Metab 2007, 92:2100-2106.
34. Mieszczak J., Lowe E.S., Plourde P., et al. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 2008, 93:2751-2754.
35. Reiter E., Mauras N., McCormick K., et al. Bicalutamide (B) plus anastrozole (A) for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). J Pediatr Endocrinol Metab 2010, 23:999-1009.
36. Geisler J., Haynes B., Anker G., et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20:3039-3040.
37. Dixon J.M., Renshaw L., Young O., et al. Letrozole suppresses plasma estradiol and estronesulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Onc 2008, 26:1671-1676.
38. Al-Omari W.R., Sulaiman W.R., Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2004, 85:289-291.
39. Santen R.J., Lee J.S., Wang S., et al. Potential role of ultrasensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids 2008, 73:1318-1321.
40. Hero M., Ankarberg-Lindgren C., Taskinen M.R., et al. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 2006, 155:453-460.
41. Hero M., Maury S., Luotoniemi E., et al. Cognitive effects of aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol 2010, 163:149-155.
42. Bilezikian J.P., Morishima A., Bell J., et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998, 339:599-603.
43. Hero M., Makitie O., Kroger H., et al. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth. and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm Res 2009, 71:290-297.
44. Hero M., Toiviainen-Salo S., Wickman S., et al. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res 2010, 25:1536-1543.
45. Turner K.J., Morley M., Atanassova N., et al. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 2000, 164:225-238.
46. Beltrame D., di Salle E., Giavini E., et al. Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits. Reprod Toxicol 2001, 15:195-213.
47. Raman J.D., Schlegel P.N. Aromatase inhibitors for male infertility. J Urol 2002, 167:624-629.
48. Kim H.H., Schlegel P.N. Endocrine manipulation in male infertility [review]. Urol Clin North Am 2008, 35:303-318.
49. Mauras N., Welch S., Rini A., et al. An open-label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH-deficient adolescent boys. J Pediatr Endocrinol Metab 2004, 17:1597-1606.
50. Mauras N., Bell J., Snow B.G., et al. Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fertil Steril 2005, 84:239-242.